Dr. Guy Chamberland returns to “Stock Day” Podcast with Everett Jolly to discuss Tetra-Biopharma
May 09 2018 - 8:30AM
Dr. Guy Chamberland, Co-Founder, Chief Scientific Officer and
Interim-CEO of Tetra-Biopharma Inc. (OTCQB:TBPMF) (TSX-V:TBP)
(“the Company”) joined Everett Jolly on Uptick Newswire’s “Stock
Day” podcast to provide an update to investors and listeners on
some recent company news.
In the interview, Dr. Chamberland described Tetra-Biopharma as a
unique and small biopharma that is developing prescription cannabis
products through the FDA and Health Canada’s regular drug channels.
Currently, one of their products is in phase III clinical trials
and is on track to be submitted to regulatory authorities.
Chamberland mentions that their hope is to get these products in
the hands of consumers as soon as possible. The FDA recently
granted the company’s product orphan drug status, which is an FDA
designation that allocates special status to drugs and/or biologics
being designed for the diagnosis, prevention, or treatment of rare
medical conditions. Tetra-Biopharma is proud of this achievement,
as orphan drug status can add more scientific credibility to their
development process and this designation will help them roll out
their products sooner. “This draws attention to our clear focus of
bringing drugs to unmet medical conditions, including chronic
pain,” says Dr. Chamberland. Updates on their lead compounds are
set to be released within the next quarter.
While the company has been successful on the drug development
side of the business, they have also signed two commercial deals
for the Israeli and Portuguese markets. These partnerships will
enable Tetra Bio-Pharma to collect upfront payments, milestone
payments, and generate a share of the profits in the sales of
PPP001. Tetra is active in discussions with companies from around
the world interested in commercializing their various products.
Once clinical trials conclude, and both the FDA and Health Canada
clear the product for distribution, the company hopes to shift
focus onto other global markets, including the European and Latin
American Markets. Canada is still in the process of legalizing
cannabis, and once that happens there will be a better platform for
the company to promote the success of their evidence-based
products.
Dr. Chamberland is confident in the direction the company is
headed with regards to the success of their clinical development,
financial position, and continued support of their investors. They
are hoping to release some news in a few weeks detailing the
benefits their products will bring to cancer and chronic pain
patients.
To hear more about Tetra-Biopharma’s product line, their efforts
to combat the opioid crisis, and more updates on their
international expansion, listen to the full interview at the link
below.
https://upticknewswire.com/featured-interview-guy-chamberland-chief-scientific-officer-of-tetra-bio-pharma-inc-2/
About Tetra Bio-Pharma
For more information, visit http://tetrabiopharma.com/
Tetra Bio-Pharma (TSX-V:TBP) (OTCQB:TBPMF) is a
biopharmaceutical leader in cannabinoid-based drug discovery and
development with a clinical program aimed at bringing novel drugs
and treatments to patients and their healthcare providers. The
Company has several subsidiaries that are engaged in the
development of Bio Pharmaceuticals and Natural Health Products
containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods
of medicinal cannabis use with the supporting scientific validation
and safety data required for inclusion into the existing bio-pharma
industry by regulators, physicians and insurance companies.
Safe Harbor Statement
Certain statements contained herein are “forward-looking
statements,” (as defined in the Private Securities Litigation
Reform Act of 1995). Tetra Bio-Pharma cautions that statements and
assumptions made in this news release constitute forward-looking
statements; the company makes no guarantee of future performance.
Forward-looking statements are based on estimates and opinions of
management at the time statements are made. These statements may
address issues that involve significant risks, uncertainties, and
other estimates made by management. Actual results could differ
from current projections or implied results. Premier Biomedical,
Inc. undertakes no obligation to revise these statements following
the date of this news release.
About Uptick Newswire Uptick Newswire is a
private company reaching out to the masses keeping investors and
shareholders up to date on company news and bringing transparency
to the undervalued, undersold, micro-cap stocks of the market and
is the sole producer of the Uptick Network “Stock Day” Podcast. The
Uptick Network “Stock Day” Podcast is an extension of Uptick
Newswire and has recently launched the Video Interview Studio
located in Phoenix, Arizona.
Investors Hangout is a proud sponsor of Uptick Newswire’s “Stock
Day” Podcast.
Contact Information
Dr. Guy Chamberland Co-Founder, CEO, CSO Tetra Bio-Pharma Inc. 1
(833) 977-7575 investors@tetrabiopharma.com
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Tetra Bio Pharma (TSXV:TBP)
Historical Stock Chart
From Sep 2023 to Sep 2024